SpyGlass Pharma (Nasdaq: SGP) reported positive clinical progress and strengthened finances after its February 2026 IPO that raised $172.5 million. The Phase 1/2 BIM-IOL System topline showed sustained IOP control and elimination of topical IOP-lowering drops in ~97% of participants at 12 months.
Phase 3 enrollment is underway, cash resources are expected to fund operations through 2028, and a BIM-DRS first-in-human trial is planned for H2 2026.
SpyGlass Pharma (NASDAQ: SGP) announced positive topline 12-month Phase 1/2 results for the BIM-IOL System on March 9, 2026. In 104 randomized patients (2:1:1), the 78-mcg and 39-mcg groups showed 34% and 42% mean IOP reductions at 8 a.m., versus 35% for control.
At 12 months 98% (78-mcg) and 96% (39-mcg) of evaluable patients were free of topical IOP medications; 100% achieved 20/32 or better BCDVA with mean BCDVA of 86 letters (≈20/20). AE rates were similar across arms; no serious ocular AEs. Two pivotal Phase 3 trials began randomizing in January 2026.
SpyGlass Pharma (Nasdaq: SGP) said its executive management team will host one-on-one meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026.
The meetings are management-led 1x1 investor sessions during the conference, offering direct Q&A opportunities.
SpyGlass Pharma (Nasdaq: SGP) closed its initial public offering of 10,781,250 shares, including full exercise of the underwriters’ option for 1,406,250 additional shares, at a public offering price of $16.00 per share on Feb. 9, 2026.
The aggregate gross proceeds were $172.5 million before underwriting discounts, commissions and offering expenses. SpyGlass Pharma began trading on the Nasdaq Global Select Market under the symbol SGP on Feb. 6, 2026. Joint book-runners were Jefferies, Leerink Partners, Citigroup and Stifel.
SpyGlass Pharma (Nasdaq: SGP) priced an initial public offering of 9,375,000 shares at $16.00 per share, generating approximately $150 million in gross proceeds before underwriting discounts and expenses. The company granted underwriters a 30-day option for an additional 1,406,250 shares.
SpyGlass Pharma common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, with the offering expected to close on February 9, 2026, subject to customary closing conditions. The registration statement became effective January 30, 2026.